Equillium Inc (EQ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.21-0.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EQ
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -83.1% |
| Our one-year growth estimate | diamond | -49.8% |
Growth built into the price is above our model estimate.
The price assumes 33.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
EQ — earnings miss
Dated 2026-05-13
of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardles…
Why it matters: Advancing EQ302 could expand Equillium's pipeline. This is important for long-term growth.
Supportive ifManagement says they made good progress on EQ302's IND-enabling work.
Worry ifNo updates or delays in the development of EQ302 are reported.
Why it matters: Developing EQ504 is key for future growth. Progress updates can signal potential success.
Supportive ifCompany announces a successful trial phase or partnership for EQ504.
Worry ifNo updates on EQ504 or news of delays in development.
Why it matters: Funding is key to keeping operations going. News can show financial health.
Worry ifThe company gets new funding or a partnership to help its operations.
Less concerning ifNo funding announcements or news of cash flow issues.
Why it matters: Keeping a strong cash position is important for funding operations. It impacts future growth.
Worry ifCash and cash equivalents are over $50 million. This confirms funding until 2029.
Less concerning ifCash and cash equivalents fall below $50 million. This raises funding concerns.
Why it matters: A drop in sector growth could impact Equillium's performance. It reflects broader industry health.
Worry ifSector revenue growth is below the median for two straight quarters.
Less concerning ifSector revenue growth remains above median.
Why it matters: Watching cash burn shows if Equillium can pay for operations until 2029.
Worry ifQ2 2026 cash burn is less than $5 million, indicating good financial control.
Less concerning ifQ2 2026 cash burn exceeds $5 million, raising concerns about funding into 2029.
Why it matters: The results will show if Equillium can fund operations into 2029. This is key for future growth.
Worry ifQ2 earnings report shows a loss less than $5 million.
Less concerning ifQ2 earnings report shows a loss greater than $5 million.
Why it matters: Watching cash burn is important. It affects funding and how long the company can operate.
Supportive ifIf cash burn rate goes down or stays steady, it shows better cost control.
Worry ifIf cash burn rate goes up a lot, it raises worries about funding until 2029.
Why it matters: If revenue growth speeds up, it could mean good news for Equillium.
Supportive ifHealth Care sector revenue growth exceeds 10% year over year.
Worry ifHealth Care sector revenue growth remains below 10% year over year.
Why it matters: Keeping cash reserves is vital for ongoing operations and plans.
Worry ifCash and cash equivalents remain above $50 million.
Less concerning ifCash and cash equivalents drop below $50 million, raising funding concerns.
Why it matters: Starting this study is key for EQ504's development. It shows progress in treating ulcerative colitis.
Supportive ifThe Phase 1 study of EQ504 is officially initiated in Q4 2026.
Worry ifThe initiation of the Phase 1 study is delayed beyond Q4 2026.
Why it matters: Topline data will provide early insights into EQ504's effectiveness. This is crucial for future studies.
Supportive ifThe Phase 1 study shows safe and effective results.
Worry ifThe Phase 1 study shows no clear safety or effectiveness.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$345 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $904 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,779 loss on $10,000 · 57.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.